Jeff Krasno

So, you know, which is like, like essentially a dysfunction around glycolysis, anaerobic respiration that leads to the proliferation of these malignant cells and a lot of metastasis. If you can quote unquote sort of starve that of glucose, there could be something there. So I think it's like doing some of these studies that combine the,

you know, fasting techniques with chemo or fasting with other forms of immunotherapies. You know, I think these are fascinating and much needed. Have you ever interviewed Thomas Seyfried?

you know, fasting techniques with chemo or fasting with other forms of immunotherapies. You know, I think these are fascinating and much needed. Have you ever interviewed Thomas Seyfried?

you know, fasting techniques with chemo or fasting with other forms of immunotherapies. You know, I think these are fascinating and much needed. Have you ever interviewed Thomas Seyfried?

Okay. I got to listen to that.

Okay. I got to listen to that.

Okay. I got to listen to that.

I mean, these are very important anecdotes because sometimes it is these outliers that then lead to more clinical study, right? So like, for example, Jimmy Carter, I believe, had like brain cancer, some sort of glioblastoma. He had this immunotherapy, which...

I mean, these are very important anecdotes because sometimes it is these outliers that then lead to more clinical study, right? So like, for example, Jimmy Carter, I believe, had like brain cancer, some sort of glioblastoma. He had this immunotherapy, which...

I mean, these are very important anecdotes because sometimes it is these outliers that then lead to more clinical study, right? So like, for example, Jimmy Carter, I believe, had like brain cancer, some sort of glioblastoma. He had this immunotherapy, which...

I believe was with the application of like a Keytruda, but then in combination with a particular probiotic, I believe this was true for Jimmy Carter, but it is definitely true now for treating some forms of cancer that immunotherapy plus like acromantia, which is a particular strain of bacteria, a beneficial strain, actually yields better results.

I believe was with the application of like a Keytruda, but then in combination with a particular probiotic, I believe this was true for Jimmy Carter, but it is definitely true now for treating some forms of cancer that immunotherapy plus like acromantia, which is a particular strain of bacteria, a beneficial strain, actually yields better results.

I believe was with the application of like a Keytruda, but then in combination with a particular probiotic, I believe this was true for Jimmy Carter, but it is definitely true now for treating some forms of cancer that immunotherapy plus like acromantia, which is a particular strain of bacteria, a beneficial strain, actually yields better results.

And so now I think they're starting to do more studies about combining immunotherapies with the right kinds of probiotics, et cetera. So this is like, you know, this is the new frontier. This is actually where AI can become very, very interesting too.

And so now I think they're starting to do more studies about combining immunotherapies with the right kinds of probiotics, et cetera. So this is like, you know, this is the new frontier. This is actually where AI can become very, very interesting too.

And so now I think they're starting to do more studies about combining immunotherapies with the right kinds of probiotics, et cetera. So this is like, you know, this is the new frontier. This is actually where AI can become very, very interesting too.

That's not my, obviously my field of expertise, but I think when you start to be able to, you know, use these large models to crunch that kind of data, this is, I think more, one of the most exciting sort of precipices of where we are.

That's not my, obviously my field of expertise, but I think when you start to be able to, you know, use these large models to crunch that kind of data, this is, I think more, one of the most exciting sort of precipices of where we are.

That's not my, obviously my field of expertise, but I think when you start to be able to, you know, use these large models to crunch that kind of data, this is, I think more, one of the most exciting sort of precipices of where we are.

Yeah, I mean, I'm generally an optimistic human being, so I'm trying to leverage that part of me. I'm worried more about, I think, general epistemology and sort of the erosion of reason and rationality and the ability to have kind of nuanced, thoughtful conversations. We live in this attention or persuasion economy, I guess you might call it, where essentially we've taken Drew's time and focus.